Who
Greg Zante
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Viking Therapeutics; VP, Finance & Administration, Sangamo Biosciences.
In numbers
- Trades disclosed
- 181
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $29.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 12 Dec 2005
- Last trade
- 29 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $710K21,217 at $33.47 | filing |
| 29 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $710K21,217 at $33.47 | filing |
| 28 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M31,961 at $32.30 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $464K13,900 at $33.38 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $353K10,300 at $34.24 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K1,500 at $32.09 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M31,961 at $32.30 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $464K13,900 at $33.38 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $353K10,300 at $34.24 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K1,500 at $32.09 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,049 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,049 at $0.00 | filing |
| 28 Oct 2025filed 28 Oct 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $216K6,185 at $35.00 | filing |
| 27 Oct 2025filed 28 Oct 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —11,117 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Greg Zante; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.